Brain Neurotherapy Bio, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2018-01-01
- Employees
- 11
- Market Cap
- -
- Website
- https://www.brainneubio.com
Gene and Cell Therapies Show Promise in Treating CNS Disorders
• The market for gene and cell therapies targeting CNS disorders was valued at approximately USD 1 billion in 2021 and is projected to grow significantly by 2034.
• Several companies are developing gene and cell therapies for CNS disorders, with some therapies already approved for conditions like spinal muscular atrophy (SMA).
• Clinical trials are showing positive trends, such as uniQure's AMT-130 for Huntington's disease demonstrating encouraging results in mean CSF NfL levels.
AskBio's AB-1005 Gene Therapy for Parkinson’s Disease Meets Primary Endpoint in Phase Ib Trial
AskBio's Phase Ib trial for AB-1005, a gene therapy targeting Parkinson’s disease, successfully met its primary endpoint, demonstrating safety and tolerability in all 11 patients over 18 months. The therapy, delivered via one-time bilateral convection-enhanced delivery to the putamen, showed no serious adverse events and exceeded target coverage goals. AskBio plans to present detailed study data in Q2 2024 and initiate a Phase II trial in the first half of 2024.
© Copyright 2025. All Rights Reserved by MedPath